Hematology · Pediatrics · 1 h ago
Inotuzumab dosing regimens compared in pediatric and AYA B-ALL
A multicentre retrospective study examined real-world outcomes in 72 children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia treated with standard or alternative inotuzumab ozogamicin dosing. Standard dosing was associated with higher composite complete response, while consolidative therapy and two-year survival outcomes did not differ between groups.
- Standard dosing was associated with higher composite complete response.
- Consolidative therapy and two-year survival did not differ.
- SOS occurred in 10%; all cases followed transplant.
Researchers retrospectively analysed 72 paediatric, adolescent and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia who received at least one dose of inotuzumab ozogamicin. Forty-one received the standard regimen and 31 received alternative dosing, which involved fewer doses or a lower cumulative dose. The study compared response, transition to consolidative cellular therapy, survival and sinusoidal obstruction syndrome (SOS).
Standard dosing was associated with a higher composite complete response rate. However, the groups did not differ in their ability to proceed to consolidative cellular therapy or in two-year event-free or overall survival. SOS occurred in 10% of patients, all after haematopoietic stem cell transplantation. Most cases followed standard dosing, but the number of events was too small to establish whether risk differed by regimen.
The findings suggest alternative dosing may still allow patients to proceed to consolidative therapy, but the retrospective design and limited SOS events constrain comparisons. The abstract does not provide response rates or other numerical outcome details.
In practice
For children, adolescents and young adults with relapsed or refractory B-cell ALL receiving inotuzumab ozogamicin, this retrospective multicentre comparison found higher composite complete response with standard dosing, but no observed difference in proceeding to consolidative cellular therapy or in two-year event-free or overall survival. The findings suggest alternative regimens may remain a possible bridge to consolidation, but they do not establish equivalent efficacy or safety. The study was not randomized, and the small number of SOS events prevents a reliable comparison of that risk.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
British Journal of Haematology: A real‐world multi‐institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B‐cell acute lymphoblastic leukaemia ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.